- Home
- GDYN vs ENGN Comparison
GDYN vs ENGN Comparison
Compare GDYN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDYN | ENGN |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.0M | 647.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GDYN | ENGN |
|---|---|---|
| Price | $5.49 | $6.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $10.67 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.6M | 513.8K |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $11.03 | N/A |
| P/E Ratio | $52.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $2.66 |
| 52 Week High | $15.87 | $12.25 |
Technical Indicators
Market Signals| Indicator | GDYN | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 28.47 |
| Support Level | N/A | $6.18 |
| Resistance Level | $7.38 | $8.14 |
| Average True Range (ATR) | 0.32 | 0.58 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 1.58 | 4.71 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.